Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Cheng, Yi-Fei  [Clear All Filters]
Journal Article
Xue Y-J, Suo P, Huang X-J, Lu A-D, Wang Y, Zuo Y-X, Yan C-H, Wu J, Kong J, Zhang X-H, et al. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukae. Br J Haematol. 2019.
Cao L-Q, Zhou J-R, Zhang X-H, Xu L-P, Wang Y, Chen Y-H, Chen H, Chen Y, Han W, Yan C-H, et al. A scoring system for predicting the prognosis of late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021.
Ma R, Zhu D-P, Zhang X-H, Xu L-P, Wang Y, Mo X-D, Lv M, Zhang Y-Y, Cheng Y-F, Yan C-H, et al. Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience. Bone Marrow Transplant. 2024.
Chen H, Xu L-P, Zhang X-H, Wang Y, Chen Y-H, Yan C-H, Cheng Y-F, Han W, Chen Y, Qin Y-Z, et al. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation. Leuk Res. 2022;121:106930.
Hu G-H, Zhang X-H, Wang Y, Xu L-P, Hou X-L, Cheng Y-F, Huang X-J. The prognosis of haploidentical hematopoietic stem cell transplantation in infants and patients under 3 years old with acute leukemia. Clin Transplant. 2024;38(2):e15247.
Bai L, Cheng Y-F, Lu A-D, Suo P, Wang Y, Zuo Y-X, Yan C-H, Wu J, Jia Y-P, Sun Y-Q, et al. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leuk Res. 2020;91:106333.
Zhang F, Hu G-H, Zhang L-P, Xu L-P, Suo P, Wang Y, Bai L, Liu K-Y, Zhang X-H, Huang X-J, et al. Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study. Leuk Lymphoma. 2023:1-6.
Hu G-H, Zhang X-H, Liu K-Y, Xu L-P, Wang Y, Cheng Y-F, Huang X-J. Outcome and prognostic factors of haploidentical allogeneic hematopoietic stem cell transplantation in pediatric relapsed or refractory ETV6/RUNX1-positive acute lymphoblastic leukemia. Acta Haematol. 2024.
Xu Z-L, Xu L-P, Zhang Y-Y, Cheng Y-F, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, et al. Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantation. Bone Marrow Transplant. 2023.
Bai L, Zhang Z-X, Hu G-H, Cheng Y-F, Suo P, Wang Y, Yan C-H, Sun Y-Q, Chen Y-H, Chen H, et al. Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre. Br J Haematol. 2023.
Yan C-H, Wang Y, Mo X-D, Sun Y-Q, Wang F-R, Fu H-X, Chen Y, Han T-T, Kong J, Cheng Y-F, et al. Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection After Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation. Clin Infect Dis. 2018;67(suppl_2):S162-S173.
Tang F-F, Cheng Y-F, Xu L-P, Zhang X-H, Yan C-H, Han W, Chen Y-H, Huang X-J, Wang Y. The incidence, risk factors, and outcomes of acute graft-vs-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation. Pediatr Transplant. 2020:e13793.
Xu Z-L, Cheng Y-F, Zhang Y-Y, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, Tang F-F, et al. The incidence, clinical outcome and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transplant. 2020:e14160.
Han T-T, Zhang Y-N, Sun Y-Q, Kong J, Wang F-R, Wang Z-D, Cheng Y-F, Yan C-H, Wang Y, Xu L-P, et al. Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft-versus-host disease. Transpl Infect Dis. 2020:e13544.
Xu L-P, Yu Y, Cheng Y-F, Zhang Y-Y, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, et al. Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. Br J Haematol. 2021.
Tang F-F, Cheng Y-F, Xu L-P, Zhang X-H, Yan C-H, Han W, Chen Y-H, Huang X-J, Wang Y. cGVHD in pediatric haplo-HSCT. Biol Blood Marrow Transplant. 2020.
Kong J, Zheng F-M, Wang Z-D, Zhang Y-Y, Cheng Y-F, Fu H-X, Lv M, Chen H, Xu L-P, Zhang X-H, et al. Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023.
Xue Y-J, Cheng Y-F, Lu A-D, Wang Y, Zuo Y-X, Yan C-H, Wu J, Sun Y-Q, Suo P, Chen Y-H, et al. Allogeneic hematopoietic stem cell transplantation, especially haploidentical HSCT, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 2018.